XML 40 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Cumulative effect of ASC 606 adoption [Member]
ViaCyte [Member]
Common Shares [Member]
Common Shares [Member]
ViaCyte [Member]
Treasury Shares [Member]
Treasury Shares [Member]
ViaCyte [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
ViaCyte [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative effect of ASC 606 adoption [Member]
Accumulated Other Comprehensive (Loss) Income [Member]
Beginning balance at Dec. 31, 2017 $ 187,832 $ (1,148)   $ 1,240       $ 312,018   $ (125,440) $ (1,148) $ 14
Beginning balance (in shares) at Dec. 31, 2017       40,592,248   444,873            
Accounting Standards Update [Extensible List] us-gaap:AccountingStandardsUpdate201409Member                      
Issuance of common shares, net of issuance costs $ 307,053     $ 311       306,742        
Issuance of common shares, net of issuance costs (in shares)       9,960,526                
Vesting of restricted shares 113     $ 1       112        
Vesting of restricted shares (in shares)       38,761                
Exercise of vested options, value 8,563     $ 26       8,537        
Exercise of vested options (in shares)       946,131   (36,253)            
Repurchase of treasury shares (57)         $ (57)            
Repurchase of treasury shares (in shares)       (64,952)   64,952            
Issuance of shares to ViaCyte     $ 15,582   $ 6       $ 15,576      
Issuance of shares to ViaCyte (in shares)         380,148   (165,636)          
Stock-based compensation expense 39,260             39,260        
Other comprehensive income (loss) (22)                     (22)
Net income (loss) (164,981)                 (164,981)    
Ending balance at Dec. 31, 2018 392,195     $ 1,584   $ (57)   682,245   (291,569)   (8)
Ending balance (in shares) at Dec. 31, 2018       51,852,862   307,936            
Issuance of common shares, net of issuance costs 414,789     $ 230       414,559        
Issuance of common shares, net of issuance costs (in shares)       7,704,068   (47,297)            
Vesting of restricted shares 43     $ 2       41        
Vesting of restricted shares (in shares)       68,009                
Exercise of vested options, value 16,001     $ 31   $ (6)   15,976        
Exercise of vested options (in shares)       1,158,860   (10,413)            
Stock-based compensation expense 49,524             49,524        
Other comprehensive income (loss) 15                     15
Net income (loss) 66,858                 66,858    
Ending balance at Dec. 31, 2019 939,425     $ 1,847   $ (63)   1,162,345   (224,711)   7
Ending balance (in shares) at Dec. 31, 2019       60,783,799   250,226            
Issuance of common shares, net of issuance costs 973,381     $ 366       973,015        
Issuance of common shares, net of issuance costs (in shares)       11,412,519                
Vesting of restricted shares 7     $ 7                
Vesting of restricted shares (in shares)       204,650                
Exercise of vested options, value $ 32,775     $ 57       32,718        
Exercise of vested options (in shares) 1,517,735     1,482,636   (37,080)            
Purchase of common stock under ESPP $ 694             694        
Purchase of common stock under ESPP (in shares)       13,410                
Issuance of shares to ViaCyte 889             889        
Issuance of shares to ViaCyte (in shares)       17,830   (17,830)            
Stock-based compensation expense 66,018             66,018        
Other comprehensive income (loss) (90)                     (90)
Net income (loss) (348,865)                 (348,865)    
Ending balance at Dec. 31, 2020 $ 1,664,234     $ 2,277   $ (63)   $ 2,235,679   $ (573,576)   $ (83)
Ending balance (in shares) at Dec. 31, 2020       73,914,844   195,316